CA1084792A - Anneau vaginal - Google Patents

Anneau vaginal

Info

Publication number: CA1084792A
Authority: CA; Canada
Prior art keywords: ring; vaginal ring; vaginal; cross; section
Prior art date: 1976-04-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA275,656A

Other languages

English (en)

Inventor

Gisela Schopflin-Hertwig

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Schering AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-04-09

Filing date

1977-04-05

Publication date

1980-09-02

1977-04-05 Application filed by Schering AG filed Critical Schering AG

1980-09-02 Application granted granted Critical

1980-09-02 Publication of CA1084792A publication Critical patent/CA1084792A/fr

Status Expired legal-status Critical Current

Links

239000006213 vaginal ring Substances 0.000 title claims abstract description 82
229940044953 vaginal ring Drugs 0.000 title claims abstract description 63
239000003814 drug Substances 0.000 claims abstract description 32
239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 13
235000013870 dimethyl polysiloxane Nutrition 0.000 claims abstract description 12
229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 11
230000006872 improvement Effects 0.000 claims abstract description 3
229920005989 resin Polymers 0.000 claims abstract description 3
239000011347 resin Substances 0.000 claims abstract description 3
239000002131 composite material Substances 0.000 claims abstract 5
229940079593 drug Drugs 0.000 claims abstract 2
229920003002 synthetic resin Polymers 0.000 claims abstract 2
239000000057 synthetic resin Substances 0.000 claims abstract 2
230000000875 corresponding effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 description 65
239000013543 active substance Substances 0.000 description 56
229920002379 silicone rubber Polymers 0.000 description 40
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 36
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
238000000465 moulding Methods 0.000 description 23
229920001296 polysiloxane Polymers 0.000 description 22
229960004400 levonorgestrel Drugs 0.000 description 20
239000004945 silicone rubber Substances 0.000 description 19
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 17
229920001971 elastomer Polymers 0.000 description 17
-1 polytetrafluorethylene Polymers 0.000 description 17
229910052697 platinum Inorganic materials 0.000 description 16
239000000126 substance Substances 0.000 description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
239000000806 elastomer Substances 0.000 description 13
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 12
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
229960002568 ethinylestradiol Drugs 0.000 description 12
238000004073 vulcanization Methods 0.000 description 12
239000000583 progesterone congener Substances 0.000 description 11
239000000377 silicon dioxide Substances 0.000 description 11
235000012239 silicon dioxide Nutrition 0.000 description 11
239000000262 estrogen Substances 0.000 description 10
238000000034 method Methods 0.000 description 10
238000010276 construction Methods 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
239000000463 material Substances 0.000 description 8
229920003023 plastic Polymers 0.000 description 8
239000004033 plastic Substances 0.000 description 8
239000003054 catalyst Substances 0.000 description 7
238000001746 injection moulding Methods 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000186 progesterone Substances 0.000 description 6
229960003387 progesterone Drugs 0.000 description 6
239000000725 suspension Substances 0.000 description 6
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
230000008901 benefit Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 5
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 5
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 5
239000000243 solution Substances 0.000 description 5
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001875 compounds Chemical group 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
150000003058 platinum compounds Chemical class 0.000 description 4
239000005060 rubber Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
229910002012 Aerosil® Inorganic materials 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
230000031018 biological processes and functions Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
239000000470 constituent Substances 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
229960000978 cyproterone acetate Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 3
229960001390 mestranol Drugs 0.000 description 3
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
229960000282 metronidazole Drugs 0.000 description 3
229960004719 nandrolone Drugs 0.000 description 3
230000016087 ovulation Effects 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
239000005871 repellent Substances 0.000 description 3
229920002631 room-temperature vulcanizate silicone Polymers 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
239000003270 steroid hormone Substances 0.000 description 3
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
241000518994 Conta Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000005840 aryl radicals Chemical class 0.000 description 2
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003433 contraceptive agent Substances 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
229960003843 cyproterone Drugs 0.000 description 2
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 2
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
229960004913 dydrogesterone Drugs 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
239000005038 ethylene vinyl acetate Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
229920003052 natural elastomer Polymers 0.000 description 2
229920001194 natural rubber Polymers 0.000 description 2
229940053934 norethindrone Drugs 0.000 description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
238000003466 welding Methods 0.000 description 2
206010063659 Aversion Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
208000012287 Prolapse Diseases 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
208000005448 Trichomonas Infections Diseases 0.000 description 1
206010044620 Trichomoniasis Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940045985 antineoplastic platinum compound Drugs 0.000 description 1
229940054053 antipsychotics butyrophenone derivative Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
IVFILROKUQKCPB-UHFFFAOYSA-N carbonyl dichloride;platinum Chemical compound [Pt].ClC(Cl)=O IVFILROKUQKCPB-UHFFFAOYSA-N 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000005266 casting Methods 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001408 fungistatic effect Effects 0.000 description 1
230000003152 gestagenic effect Effects 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
239000011796 hollow space material Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
238000007654 immersion Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
231100000546 inhibition of ovulation Toxicity 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003961 organosilicon compounds Chemical class 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
150000003606 tin compounds Chemical class 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
UMFCIIBZHQXRCJ-NSCUHMNNSA-N trans-anol Chemical compound C\C=C\C1=CC=C(O)C=C1 UMFCIIBZHQXRCJ-NSCUHMNNSA-N 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
125000005023 xylyl group Chemical group 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

Health & Medical Sciences (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Materials For Medical Uses (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA275,656A 1976-04-09 1977-04-05 Anneau vaginal Expired CA1084792A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DEP2616064.5		1976-04-09
DE19762616064 DE2616064A1 (de)	1976-04-09	1976-04-09	Vaginalring iii

Publications (1)

Publication Number	Publication Date
CA1084792A true CA1084792A (fr)	1980-09-02

Family

ID=5975198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA275,656A Expired CA1084792A (fr)	1976-04-09	1977-04-05	Anneau vaginal

Country Status (17)

Country	Link
JP (1)	JPS52124798A (fr)
AU (1)	AU517915B2 (fr)
BE (1)	BE853429R (fr)
CA (1)	CA1084792A (fr)
CS (1)	CS197289B2 (fr)
DD (1)	DD129162A6 (fr)
DE (1)	DE2616064A1 (fr)
DK (1)	DK157477A (fr)
ES (1)	ES457629A2 (fr)
FR (1)	FR2347053A2 (fr)
GB (1)	GB1581474A (fr)
HU (1)	HU176165B (fr)
IE (1)	IE44736B1 (fr)
IT (1)	IT1115641B (fr)
NL (1)	NL7703651A (fr)
SE (1)	SE7703981L (fr)
SU (1)	SU833144A3 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2618329B1 (fr) *	1987-07-22	1997-03-28	Dow Corning Sa	Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
FI95768C (fi) *	1993-06-17	1996-03-25	Leiras Oy	Emättimensisäinen antosysteemi
DK0836473T3 (da)	1995-07-04	2002-02-11	Akzo Nobel Nv	Ringformede indretninger
WO1999056934A1 (fr) *	1998-05-01	1999-11-11	Fei Enterprises, Ltd.	Procede de fabrication par moulage par injection pour dispositifs de liberation controlee
CN103298519B (zh)	2010-11-12	2016-09-14	犹他大学研究基金会	用于受控式润滑剂传递的阴道内装置
CN104971414A (zh) *	2014-04-01	2015-10-14	黄震山	药物缓释器
US20170224823A1 (en) *	2014-10-22	2017-08-10	International Partnership For Microbicides, Inc.	Platinum-catalyzed silicone drug delivery devices and methods of use thereof
US10918649B2 (en) *	2019-06-21	2021-02-16	The Population Council, Inc.	System for providing birth control
US11529308B2 (en)	2019-06-21	2022-12-20	The Population Council, Inc.	System for providing birth control

1976
- 1976-04-09 DE DE19762616064 patent/DE2616064A1/de not_active Withdrawn
1977
- 1977-04-04 NL NL7703651A patent/NL7703651A/xx not_active Application Discontinuation
- 1977-04-05 CA CA275,656A patent/CA1084792A/fr not_active Expired
- 1977-04-05 SE SE7703981A patent/SE7703981L/xx unknown
- 1977-04-05 CS CS772252A patent/CS197289B2/cs unknown
- 1977-04-06 DK DK157477A patent/DK157477A/da not_active IP Right Cessation
- 1977-04-06 IE IE727/77A patent/IE44736B1/en unknown
- 1977-04-06 AU AU24055/77A patent/AU517915B2/en not_active Expired
- 1977-04-06 ES ES457629A patent/ES457629A2/es not_active Expired
- 1977-04-07 IT IT22201/77A patent/IT1115641B/it active
- 1977-04-07 GB GB14825/77A patent/GB1581474A/en not_active Expired
- 1977-04-07 DD DD7700198315A patent/DD129162A6/xx unknown
- 1977-04-08 BE BE176575A patent/BE853429R/fr active
- 1977-04-08 SU SU772468507A patent/SU833144A3/ru active
- 1977-04-08 JP JP4025277A patent/JPS52124798A/ja active Pending
- 1977-04-08 HU HU77SCHE600A patent/HU176165B/hu unknown
- 1977-04-12 FR FR7710882A patent/FR2347053A2/fr active Granted

Also Published As

Publication number	Publication date
FR2347053A2 (fr)	1977-11-04
SE7703981L (sv)	1977-10-10
AU517915B2 (en)	1981-09-03
NL7703651A (nl)	1977-10-11
FR2347053B2 (fr)	1980-07-04
IT1115641B (it)	1986-02-03
IE44736L (en)	1977-10-09
IE44736B1 (en)	1982-03-10
GB1581474A (en)	1980-12-17
ES457629A2 (es)	1978-11-16
SU833144A3 (ru)	1981-05-23
JPS52124798A (en)	1977-10-20
CS197289B2 (en)	1980-04-30
DE2616064A1 (de)	1977-10-20
DD129162A6 (de)	1978-01-04
HU176165B (en)	1980-12-28
DK157477A (da)	1977-10-10
BE853429R (fr)	1977-10-10
AU2405577A (en)	1978-10-12

Legal Events

Date	Code	Title	Description
1997-09-02	MKEX	Expiry

Publication	Publication Date	Title
IE42345B1 (en)	1980-07-16	Vaginal ring
US4155991A (en)	1979-05-22	Vaginal ring
CA1298688C (fr)	1992-04-14	Anneaux therapeutiques
JP3970936B2 (ja)	2007-09-05	挿入自在の薬剤含有コアを有する膣内リング
US4822616A (en)	1989-04-18	Vaginal ring
US4292965A (en)	1981-10-06	Intravaginal ring
US4012497A (en)	1977-03-15	Drug excipient of silicone rubber
WO1998004220A9 (fr)	1998-05-28	Anneau vaginal a noyau inserable contenant un medicament
JP2012040400A (ja)	2012-03-01	プロゲステロン受容体モジュレーターを含有する徐放性組成物
EP0981327A2 (fr)	2000-03-01	Dispositifs intravaginaux servant a administrer du testosterone ou des precurseurs de testosterone
US5558877A (en)	1996-09-24	Method and device for treatment of cancer
US20110208135A1 (en)	2011-08-25	Intravaginal delivery system and process for manufacturing it
EP0970704B1 (fr)	2002-09-11	Implant avec un noyau en silicone pour une libération prolongée d'androgène
EP0791354B1 (fr)	2003-01-15	Procédé de fabrication de dispositifs à libération contrôlée
JPS62298532A (ja)	1987-12-25	膣挿入デバイス
IE44736B1 (en)	1982-03-10	Vaginal ring
EP1494646B1 (fr)	2012-07-11	Dispositifs d'apport par voie vaginale d'un medicament present dans une matrice
CA1084791A (fr)	1980-09-02	Anneau vaginal
WO1992018101A1 (fr)	1992-10-29	Dispositif d'administration vaginale de substances medicamenteuses
MXPA98002349A (en)	1998-11-12	Intravaginal rings with insertable drug-containing core